Effects of Levothyroxine Replacement Therapy on Parameters of Metabolic Syndrome and Atherosclerosis in Hypothyroid Patients: A Prospective Pilot Study

Abstract

The aim of this study was to investigate the effect of levothyroxine (LT4) replacement therapy during three months on some parameters of metabolic syndrome and atherosclerosis in patients with increased thyroid-stimulating hormone (TSH) level. This study included a group of 30 female patients with TSH level >4 mIU/L and 15 matched healthy controls. Intima media complex thickness (IMCT) and peak systolic flow velocity (PSFV) of superficial femoral artery were determined by Color Doppler scan. In hypothyroid subjects, BMI, SBP, DBP, and TSH were significantly increased versus controls and decreased after LT4 administration. FT4 was significantly lower in hypothyroid subjects compared with controls and significantly higher by treatment. TC, Tg, HDL-C, and LDL-C were similar to controls at baseline but TC and LDL-C were significantly decreased by LH4 treatment. IMCT was significantly increased versus controls at baseline and significantly reduced by treatment. PSFV was similar to controls at baseline and significantly decreased on treatment. In this study, we have demonstrated the effects of LT4 replacement therapy during three months of treatment on correction of risk factors of metabolic syndrome and atherosclerosis.

Effect of Hyperbaric Oxygen Therapy on Fatty Acid Composition and Insulin-like Growth Factor Binding Protein 1 in Adult Type 1 Diabetes Mellitus Patients: A Pilot Study

“…Sun et al reported that an increased level of lipoproteins and decreased level of HDL-C was associated with a higher incidence of cardiovascular disease (33). However, we did not find any significant effect of HBOT on the level of HDL-C, probably due to other parameters, such as age and diet (34,35). Another reason for not detecting a significant effect on HDL-C could lie in the small sample size and small effect size.…”

The association between adherence to levothyroxine and economic and clinical outcomes in patients with hypothyroidism in the US

“…However, untreated hypothyroidism has been shown to increase the risk of heart failure 48,49 as well as coronary heart disease (CHD) and CHD-related death 10 . In this study, adherent patients were found to be more likely to have comorbid dyslipidemia, despite the fact that LT4 treatment usually corrects dyslipidemia 50 . However, in cases where LT4 therapy does not correct dyslipidemia, other factors, such as genetics, age or diet, may be involved 50 .…”

“…In this study, adherent patients were found to be more likely to have comorbid dyslipidemia, despite the fact that LT4 treatment usually corrects dyslipidemia 50 . However, in cases where LT4 therapy does not correct dyslipidemia, other factors, such as genetics, age or diet, may be involved 50 .…”

Variations of physiological parameters in newly detected hypothyroidism

“…It was observed that pulse rate and respiratory rate had no significant difference with age groups while both systolic and diastolic blood pressures show significant variations (p value<0.05) with higher blood pressure in 36-45 years age group. 14 (Table 3) T3 has direct vasodilator action on vascular smooth muscle cells, so in hypothyroidism due to reduced T3 levels, vascular smooth muscle tone increases and systemic vascular resistance increases. 8 Endothelial dysfunction also affects systemic vascular resistance.…”